Literature DB >> 33060101

Centrally Reduced Diffusion Sign for Differentiation between Treatment-Related Lesions and Glioma Progression: A Validation Study.

P Alcaide-Leon1, J Cluceru2, J M Lupo2, T J Yu2, T L Luks2, T Tihan3, N A Bush4, J E Villanueva-Meyer5.   

Abstract

BACKGROUND AND
PURPOSE: Differentiating between treatment-related lesions and tumor progression remains one of the greatest dilemmas in neuro-oncology. Diffusion MR imaging characteristics may provide useful information to help make this distinction. The aim of the study was to assess the diagnostic accuracy of the centrally reduced diffusion sign for differentiation of treatment-related lesions and true tumor progression in patients with suspected glioma recurrence.
MATERIALS AND METHODS: The images of 231 patients who underwent an operation for suspected glioma recurrence were reviewed. Patients with susceptibility artifacts or without central necrosis were excluded. The final diagnosis was established according to histopathology reports. Two neuroradiologists classified the diffusion patterns on preoperative MR imaging as the following: 1) reduced diffusion in the solid component only, 2) reduced diffusion mainly in the solid component, 3) no reduced diffusion, 4) reduced diffusion mainly in the central necrosis, and 5) reduced diffusion in the central necrosis only. Diagnostic accuracy metrics and the area under the receiver operating characteristic curve were estimated for the diffusion patterns.
RESULTS: One hundred three patients were included (22 with treatment-related lesions and 81 with tumor progression). The diagnostic accuracy results for the centrally reduced diffusion pattern as a predictor of treatment-related lesions ("mainly central" and "exclusively central" patterns versus all other patterns) were as follows: 64% sensitivity (95% CI, 41%-83%), 84% specificity (95% CI, 74%-91%), 52% positive predictive value (95% CI, 37%-66%), and 89% negative predictive value (95% CI, 83%-94%).
CONCLUSIONS: The centrally reduced diffusion sign is associated with the presence of treatment effect. The probability of a histologic diagnosis of a treatment-related lesion is low (11%) in the absence of centrally reduced diffusion.
© 2020 by American Journal of Neuroradiology.

Entities:  

Mesh:

Year:  2020        PMID: 33060101      PMCID: PMC7658838          DOI: 10.3174/ajnr.A6843

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  17 in total

1.  Diagnostic accuracy of diffusion MRI with quantitative ADC measurements in differentiating glioma recurrence from radiation necrosis.

Authors:  Hui Zhang; Li Ma; Cheng Shu; Yu-Bo Wang; Lian-Qiang Dong
Journal:  J Neurol Sci       Date:  2015-02-28       Impact factor: 3.181

2.  Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.

Authors:  Woong Jae Lee; Seung Hong Choi; Chul-Kee Park; Kyung Sik Yi; Tae Min Kim; Se-Hoon Lee; Ji-Hoon Kim; Chul-Ho Sohn; Sung-Hye Park; Il Han Kim
Journal:  Acad Radiol       Date:  2012-08-11       Impact factor: 3.173

3.  Diffusion measurements in intracranial hematomas: implications for MR imaging of acute stroke.

Authors:  S W Atlas; P DuBois; M B Singer; D Lu
Journal:  AJNR Am J Neuroradiol       Date:  2000-08       Impact factor: 3.825

4.  Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.

Authors:  A J Prager; N Martinez; K Beal; A Omuro; Z Zhang; R J Young
Journal:  AJNR Am J Neuroradiol       Date:  2015-01-15       Impact factor: 3.825

5.  Differentiation between brain tumor recurrence and radiation injury using perfusion, diffusion-weighted imaging and MR spectroscopy.

Authors:  Barbara Bobek-Billewicz; Gabriela Stasik-Pres; Henryk Majchrzak; Lukasz Zarudzki
Journal:  Folia Neuropathol       Date:  2010       Impact factor: 2.038

6.  Diagnostic Accuracy of Centrally Restricted Diffusion in the Differentiation of Treatment-Related Necrosis from Tumor Recurrence in High-Grade Gliomas.

Authors:  N Zakhari; M S Taccone; C Torres; S Chakraborty; J Sinclair; J Woulfe; G H Jansen; T B Nguyen
Journal:  AJNR Am J Neuroradiol       Date:  2017-12-07       Impact factor: 3.825

7.  Distinction between glioma progression and post-radiation change by combined physiologic MR imaging.

Authors:  Eiji Matsusue; James R Fink; Jason K Rockhill; Toshihide Ogawa; Kenneth R Maravilla
Journal:  Neuroradiology       Date:  2009-10-16       Impact factor: 2.804

8.  Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury.

Authors:  Patrick A Hein; Clifford J Eskey; Jeffrey F Dunn; Eugen B Hug
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

9.  Parametric Response Mapping of Apparent Diffusion Coefficient as an Imaging Biomarker to Distinguish Pseudoprogression from True Tumor Progression in Peptide-Based Vaccine Therapy for Pediatric Diffuse Intrinsic Pontine Glioma.

Authors:  R Ceschin; B F Kurland; S R Abberbock; B M Ellingson; H Okada; R I Jakacki; I F Pollack; A Panigrahy
Journal:  AJNR Am J Neuroradiol       Date:  2015-09-03       Impact factor: 3.825

10.  Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI.

Authors:  S Wang; M Martinez-Lage; Y Sakai; S Chawla; S G Kim; M Alonso-Basanta; R A Lustig; S Brem; S Mohan; R L Wolf; A Desai; H Poptani
Journal:  AJNR Am J Neuroradiol       Date:  2015-10-08       Impact factor: 3.825

View more
  3 in total

1.  The centrally restricted diffusion sign on MRI for assessment of radiation necrosis in metastases treated with stereotactic radiosurgery.

Authors:  Nicolin Hainc; Noor Alsafwani; Andrew Gao; Philip J O'Halloran; Paul Kongkham; Gelareh Zadeh; Enrique Gutierrez; David Shultz; Timo Krings; Paula Alcaide-Leon
Journal:  J Neurooncol       Date:  2021-10-24       Impact factor: 4.130

2.  Assessment of the hypervascularized fraction of glioblastomas using a volume analysis of dynamic susceptibility contrast-enhanced MRI may help to identify pseudoprogression.

Authors:  Margaux Roques; Isabelle Catalaa; Magali Raveneau; Justine Attal; Aurore Siegfried; Jean Darcourt; Christophe Cognard; Nicolas Menjot de Champfleur; Fabrice Bonneville
Journal:  PLoS One       Date:  2022-10-13       Impact factor: 3.752

3.  Combined Diagnostic Accuracy of Diffusion and Perfusion MR Imaging to Differentiate Radiation-Induced Necrosis from Recurrence in Glioblastoma.

Authors:  Ankush Jajodia; Varun Goel; Jitin Goyal; Nivedita Patnaik; Jeevitesh Khoda; Sunil Pasricha; Munish Gairola
Journal:  Diagnostics (Basel)       Date:  2022-03-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.